Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

2019691 citationsJournal Articlegreen Open Access

Authors

Alok A. Khorana · Cleveland Clinic

Gerald A. Soff · Cornell University

Ajay K. Kakkar · University College London

Saroj Vadhan‐Raj · The University of Texas MD Anderson Cancer Center

Hanno Riess · Charité - Universitätsmedizin Berlin

Ted Wun · University of California, Davis

Michael B. Streiff

Abstract

In high-risk ambulatory patients with cancer, treatment with rivaroxaban did not result in a significantly lower incidence of venous thromboembolism or death due to venous thromboembolism in the 180-day trial period. During the intervention period, rivaroxaban led to a substantially lower incidence of such events, with a low incidence of major bleeding. (Funded by Janssen and others; CASSINI ClinicalTrials.gov number, NCT02555878.).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Central Venous Catheters and Hemodialysis Atrial Fibrillation Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 8, pp. 720-728

DOI: 10.1056/nejmoa1814630

Field-Weighted Citation Impact: 84.33